Navigation Links
New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated

SCOTTSDALE, Ariz., April 3, 2008 /PRNewswire/ -- In this report, entitled "MedPredict Thought Leader Insight & Analysis: Pharmacotherapies for Alcoholism," physician experts discuss the key controversies surrounding development of drugs for alcoholism, and why they think the biopharmaceutical industry is underestimating the size of this market.

According to this physician panel, there are a number of factors stymieing biopharmaceutical companies, including the lackluster commercial performance of naltrexone and acamprosate, a lack of clear FDA guidance on trial design and resulting indications, the stigma associated with alcoholism and associated corporate image risks, and the tremendous fear of product liability litigation. The general corporate perception is that drugs for alcoholism won't be reimbursable, and many of the people who come in for treatment will not be able to afford medicine.

"An analogy would be to attempt to forecast the size of the antidepressant market before the availability of Prozac," according to Dr. Jeff Berk, the report's principal author. "While competitive intensity in the alcoholism field has been low by traditional measures, it is clearly now emerging. We expect to see tremendous growth after the first successful product launches into the primary care physician's office."
Also addressed by MedPredict's panel:

-- Unmet needs from the patient, specialist, general practitioner,

3rd-party payer and societal perspective,

-- Habits & practices of specialists, general practitioners and

non-medical treaters,

-- Hurdles preventing increased diagnosis and treatment of alcoholism,

particularly in the community setting, and a commercialization model

that Pharma can follow to overcome these,

-- Changing paradigms in primary and secondary clinical trial endpoints

and alcoholism trial designs, and

-- New screening tools and behavioral diagnostic instruments.

Drugs/classes mentioned in this report: ReVia (naltrexone); Vivitrol (extended release injectable naltrexone; Alkermes / Cephalon); Campral (acamprosate; Forest); Antabuse (disulfiram); gabapentin (generic); Topamax (topiramate; Ortho-McNeil); Prometa (flumazanil / gabapentin / hydroyzine; Hythiam); glutamatergic; non-NMDA; kainate; AMPA; CB-1; Acomplia (rimonabant; Sanofi-Aventis); SSRI; dopaminergic; Seroquel (quetiapine; AstraZeneca); NPY; NK; CRH.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
2. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):